Fluoropharma Medical Inc · OTC:FPMI
Fluoropharma Medical — Investor Presentation (December 2013)
49 slides from Fluoropharma Medical's investor presentation, Dec 5, 2013
Slide 1: Enabling Personalized Medicine Through Precision Diagnostics
Fluoro —— _— Pharma Enabling Personalized Medicine Through Precision Diagnostics.
Slide 2: Forward-Looking Statements
Fluoro — Forward-Looking Statements Pharr This presentation contains “forwarcHooking statements” within the meaning of the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which are intended to be covered b
Slide 3: Patients will die of heart disease
www.FluoroPharma.com Patients will die of heart disease A cardiac perfusion scan is performed Portfolio of compounds in heart disease * CardioPET
Slide 4: FluoroPharma At-a-Glance
FluoroPharma At-a-Glance Pharma THE COMPANY CORE EXPERTISE THREE ACTIVE CARDIAC IMAGING PROGRAMS FOR PET IMAGING CLINICAL BENEFITS PATIENT MANAGEMENT. www.FluoroPharma.com Founded in 2003 in Boston with technology licensed from Massachusetts General Hospital Next generation molecular imaging drugs f
Slide 5: Investment Highlights
Fluoro — Investment Highlights ~ Pharma Proprietary products that support new technologies for personalized medicine + Next generation / first-in-class diagnostic imaging * Helps determine the course of cardiac treatment Two Phase Il-ready products with short study timelines. both directed to very l
Slide 6: BFPET high resolution differentiates ischemic, infarcted and healthy myocardium
BFPET's extremely high resolution allows the cardiologist to differentiate among ischemi infarcted, and healthy myocardium. As shown below, BFPET images have higher resolution than market-standard sestamibi on a qualitative basis. Sestamibi Standard of Care | On SPECT this patient appeared to have a
Slide 7: Product candidates: BFPET, CardioPET, VasoPET
17 million potential patients 56 million potential patients For use in combination with stress-testing in patients with presumptive chronic CAD To replace SPECT in institutions with PET capability Phase 2 (U.S., China) Launch 2016 U.S. patent through 2025 Perfusion images Detects regions of fatty ac
Slide 8: @ rere synch 2008
@ rere synch 2008 seecie 3/8/13.11:3803 AM Made in Ost
Slide 9: Global Market for PET/SPECT (2010-2020)
Global Market for PET/SPECT (2010-2020) PET new unit sales projected to exceed SPECT by 2017 , Pharma Global Market for PET/SPECT, 2010-2016, $ billions (Overall Global Installed Bases of PET/SPECT Systems, 2010-2016 7000 2010 2011 2012 2013 2014 2015 2016 2010 2011 2012 2013 2014 2015 2016 alee cai
Slide 10: Substantial Installed Base in the US
Substantial Installed Base in the US Pharma Cardiacstess tests are already performed more than 60% of the time at centers with PET machines. Distribution of PET Machinesin US Hospitals, 2010+ SwFuoroPharm
Slide 11: PET Predicted to grow to 1/3 of U.S. nuclear cardiology procedures
PET Predicted to grow to 1/3 of U.S. nuclear cardiology procedures Fluoro —— ~ Pharma Approximate Use of Cardiac Diagnostic Testing 100% 90% (uN Lo upeady uonezuaujed yg ssang 4pjn98 o/1e 310 H ' h \ Future of Nuclear Cardiologyin 2020 SPECT & SPECT/CT PET & PET/CT - 0% 50% 100% Source: Nuclear Card
Slide 12: Production of Finished Material
Production of Finished Material US Cyclotron Distribution Network Pharma Approximately 100 FDG production sites (Cardinal Health, IBA, PETNET) will allow FluoroPharma to providea high level of customerservice, enabling product delivery within two to three hoursto 85% of PET institutions nationwide.
Slide 13: Why PET now
Why PET now: Fluoro — Distribution, infrastructure and increased install base Pharr , , * PET has a significantly higher rate of specificity and sensitivity than SPECT Paradigm shiftto + Leads to decreased attenuation artifacts and fewer inconclusive studies Weigel) . providesa more accurate diagnos
Slide 14: Large, Growing Market for Imaging Agents
Large, Growing Market for Imaging Agents = Pharma Imaging Drug Market * Global market projected to exceed $15 billion by 2015 Worldwide Sales Forecast + Fueled by need for personalized medicine : 16 $158 Total + Additional drivers include: 14 2 gi2 $7B Total % * Growing volume of diagnostic examinat
Slide 15: Product Portfolio Market Size and Revenue Opportunity
Product Portfolio Market Size and Revenue Opportunity Pharma BFPET CardioPET VasoPET 12.0m 174m 55.5m 30-50% 30-50% 15% 3.6-6.0m 5.287m 0.9m FPMIPET 40-90% 21-41% 100% Market Shar 1454m 133.6m 0.9m FPMI Pr FPMI Price Per $600 $600 $600 Dose * $0.93.2B $0.8:2.2B $510M Sources Gampbel Alone f estates
Slide 16: BFPET Clinical Use
BFPET Clinical Use ~ Pharma MYOCARDIAL PERFUSION IMAGING * Evaluate patients with known or suspected CAD + Evaluate CAD in patients that can tolerate exercise as well as pharmacologic stress CURRENT DIAGNOSTIC TEST * Perfusion imaging with SPECT tracers (e.g. MIBI, tetrophosmin, TI-201) or Rb-82 CLI
Slide 17: BFPET Phase I Trial Findings
BFPET Phase] Trial Findings ; Pharr * Rapid extraction from blood * Stable heart uptake overtime * High target to background ratios * Convenientimaging window * Whole body effective dose: 73.5 + + 12 healthy volunteers ages 20-85 + No adverse events * No Clinically significant changes noted in follo
Slide 18: Slide 18
Slide 19: The BFPET Opportunity
Fluoro — The BFPET Opportunity ~ Pharma Projected BFPET Scans MILLIONS 14 Est. 5 Year Revenue $691 million Est. PET Market Procedures Market Size Myocardial perfusion 12 million 3.6 million imaging - Year1 Year3 Year5 www.FluoroPharma.com
Slide 20: BFPET high resolution differentiates ischemic, infarcted and healthy myocardium
BFPET's extremely high resolution allows the cardiologist to differentiate among ischemi infarcted, and healthy myocardium. As shown below, BFPET images have higher resolution than market-standard sestamibi on a qualitative basis. Sestamibi Standard of Care | On SPECT this patient appeared to have a
Slide 21: CardioPET Clinical Use
CardioPET Clinical Use ~ Pharma CARDIAC VIABILITY ASSESSMENT * Identify patients that may benefit from PCI or revascularization and guide intervention + Evaluate CAD in patients that cannot exercise CURRENT TREATMENT * Invasive coronary angiography CLINICAL NEED + 13 million diagnostic angiography p
Slide 22: CardioPET fatty acid analog detects metabolic insufficiency
Fatty acid analog that detects regions of metabolic insufficiency PHASE IT (15 NHV and 6 CAD patients) * CardioPET promising safety with no AEs detected * Clinical findings consistent with MPI SPECT * Quality of CardioPET images substantially superior to MPI SPECT Infarcted region of the heart 45 mi
Slide 23: nsverse Transverse
nsverse Transverse MPR MPR a | Coronal = a 1 = R76 dynamic (AC) Anterior / | ——— — ee
Slide 24: Slide 24
Slide 25: The CardioPET Opportunity
The CardioPET Opportunity Pharma Projected CardioPET Scans MILLIONS Assumption: 20 Est. 5" Year Revenue $605 million me Est. PET Est. FP Market Procedures warketSize Share = CAD diagnosis 3 smition 1.4 million 32% 08 atrest Cardiac viability 4 & mition 0.5 million 80% 04 assessment Myocardial 0.0 pe
Slide 26: VasoPET Indications and Clinical Use
Fluoro — VasoPET Indications and Clinical Use = Pharma EVALUATION OF * Patients with acute cardiac event or stroke (risk of recurring event) * Therapy following acute cardiac event or stroke (e.g. Plavix, lipid therapy, new treatments) CURRENT DIAGNOSTIC PRACTICE * Clinical symptoms; several imaging
Slide 27: Detection Of Inflamed Atherosclerotic Plaque
Detection Of Inflamed Atherosclerotic Plaque WHY INFLAMMATION IMAGING? * Diagnosis before symptoms occur * Crucial role at all stages of atherosclerosis * Mayaid drug development ul ‘ DEVELOPMENT STATUS + Preciinical testing completed + IND preparation ongoing * Plan to initiate Phase! proof of prin
Slide 28: Clinical drivers Advancing the Transition to PET in Clinical Cardiology
Clinical drivers Advancing the Transition to PET in Clinical Cardiology ~ Pharma Drivers and Benefits: © Expansion of clinical indications/clinical needs Lower radiation dose Improved diagnostic accuracy Improved patient outcomes © Continued advancements in scanner technology Fusion of anatomical an
Slide 29: Experienced Management Team and Advisors
Fluoro Experienced Management Team and Advisors — Pharma Thijs Spoor President, CEO + Healthcare executive with >45 years medical industry experience + Former securities analyst at J.P. Morgan and Credit Suisse covering medical devices and biotechnology + Led the nuclear cardiology portfolio and PET
Slide 30: Growth Strategy / Near-Term Milestones
Growth Strategy / Near-Term Milestones Fluoro — ~ Pharma Capitalize on multiple cardiovascular molecular imaging agents for PET * Cardiac viability assessment * Myocardial perfusion imaging * Inflamed atherosclerotic plaque imaging Address unmet needs in cardiovascular diagnostics by providing + Dia
Slide 31: 31
31 www.FluoroPharma.com
Slide 32: The Next Big Step in Healthcare
Fluoro The Next Big Step in Healthcare ic Pha na MEDICINE TODAY One treatment fits all - =» still a guessing game www.FluoroPharma.com ae
Slide 33: Personalized Diagnosis
Personalized Diagnosis MEDICINE TOMORROW must be personalized Right Treatment for the Right Patient at the Right Time for the Right Outcome gy Before you can see it, Before the patient feels it, We can identify it Personalized medicine begins with the right diagnosis www.FluoroPharma.com “se
Slide 34: Unmet Need for Better Imaging Methods
Fluoro — Unmet Need for Better Imaging Methods — Pharma FDA Warning in 2007 * Nephrogenic systemic fibrosis for Gadolinium-based contrast agents FDA Warning in 2007 ANATOMICAL =» a IMAGING + Deaths and serious cardiopulmonary reactions arising from marketed products. None srvesecopune He Pc ~ Fluoro
Slide 35: PET Imaging Roots are in Oncology
PET Imaging Roots are in Oncology Pharma PET procedures by disease area 2500 @ 2000 g ze g g = Cardiology < 1500 and = » neurology 3 remain EF 4000 strong growth ui opportunities 500 0 2004 2005 2006 2007 2008 2005 Year HH Oncology Ml Neurology ll Cardiology 25 Source: Frost & Sullivan 2008 www.Fluo
Slide 36: Cardiovascular Disease is the Next Big Opportunity
Fluoro ~ Cardiovascular Disease is the Next Big Opportunity _— Pharma Total diagnostic radiopharmaceutical agents market: Cardiac imaging procedures are the greatest opportunity to switch to PET 25, Procedures (millions) 219 Dae 201 218 20.4 cae | CAGR =~ J JI j ‘07-09 PET (Total) 17.0% 45 SPECT (Ca
Slide 37: Technical Trends - Growth drivers enabling shift in technology
Technical Trends - Growth drivers enabling shift in technology Technical and Diagnostic Benefits of PET vs. SPECT ~ Pharma Image + Improved overall image quality + Dynamic tomographic imaging + High Definition Hybrid imaging: calcium scoring, CT angiography + Improved spatial, temporal and contrast
Slide 38: FluoroPharma Enables Personalized Diagnosis
FluoroPharma Enables Personalized Diagnosis — Pharma Imaging provides non-invasive tools with immediate personalized recommendations for treatment Spatial + Allows direct visual evaluation of bt Resolution disease on a molecular level * Measures the efficacy of treatment Ultrasound * Tracks response
Slide 39: Poised to Capture Cardio Diagnostics
Poised to Capture Cardio Diagnostics = Pharma Cardiovascular Diagnostics PET Molecular Imaging + 1Lin-3 adults havesome form of CV + Superior image quality disease * PETis alarge and rapidly growing * $403 billion: fully burdened cost of imaging platform CAD. * Increasing demand for PET * ~ 12 milli
Slide 40: Robust Portfolio On-Track
Fluoro — Robust Portfolio On-Track ~ Pharma Market | Patients Drug / Indication Patent | Licens Pre- IND I " ul NDA e clinical CardioPET $08-228 17.4M Prostate Cancer $093.28 12.0M VasoPET ‘$510M EERIE = Vulnerable plaque coronary Carotid coronary perforation Vulnerable plaque carotid Sources: Campb
Slide 41: The VasoPET Opportunity
Fluoro — The VasoPET Opportunity ~ Pharma Projected VasoPET Scans MILLIONS 08 Est. 5 Year Revenue 07 $408 million 06 Market Patients Bee Hulse we Size s er 04 creening for atherosclerosis 50 million 300,000 03 02 Responseto 3 gmillion 380,000 therapy (statins) 04 Followupafter 4 9 milion 90,000 0 he
Slide 42: Targets Greatest Areas for Cost Reduction
Targets Greatest Areas for Cost Reduction Pharma Therapeutics aimed to prevent and best treat disease related to diabetes, obesity and heart disease hold greatest promise Pharmaceuticals enabling personalized, outcomes-driven medicine offer greatest route to reducing the overall costs of healthcare
Slide 43: Molecular imaging value chain players
Molecular Pharmaceutical Distribution IBA Molt Siemet PETNET Development Multiple players in each value chain www.FluoroPharma.com
Slide 44: The cycle of classic medicine is reactive medical care
Fluoro — The cycle of classic medicine is reactive medical care Pharma Reactive Medical Care Drug Again Switch Drug Select Drug Disease Severity Time Diagnose Disease; Treat Symptoms; Costly, Trial and Error Treatment 44 Personalized Medicine Coalition; Abrahams Presentation www.FluoroPharma.com
Slide 45: Shifting to outcomes focused personalized treatments increases efficiency
Fluoro — Shifting to outcomes focused personalized treatments increases efficiency — Pharma Efficient Medical Care “Right Drug” Disease Severity Diagnosis / Prognosis Diagnosis Health Management; Molecular Screening; Early Detection; Rapid Effective Treatment; Improved Quality of Care 45 Personalize
Slide 46: Cardiovascular Disease
Cardiovascular Disease ~ Pharma rey, KEY FACTS - US AND WW WHO: “Neglected Global Epidemic + 16.7M deaths WW: 1/3 of all deaths, 78% from low / middle income countries. * 1/3 of deaths in China, ¥2 in Europe + 2.4M deaths US: top cause (38.5%) Malignant Arrhythmias (S High Blood Pressure Coronary Ar
Slide 47: Outcomes partnerships drive clinical trial endpoints
Outcomes partnerships drive clinical trial endpoints _— Pharma ic pressures PAST FUTURE Fragmented, gy ge Gg Sd Ye & Integrated, non-systems————_ soé—rstems of of care Decisions by individual st 7 eae delivery (ul Aligned (1) Conventional (Il) Complex Multistakeholder for Ouleomes Predominant Hep. M
Slide 48: Market Drivers for New PET Products
Market Drivers for New PET Products = Pharma Growth in PET ural volumes Low capacity Comprehensive adoption of early utilization diagnosis will improve utilization of technology 2000 + Atcapacity, more patients could be diagnosed earlier leading to better patient outcomes jons) 4,740 6 Unutiized 4 *
Slide 49: Thank you for listening!
Fluoro —— _— Pharma Thank you for listening!
FluoroPharma Medical — Investor Presentation (December 2013) on 6ix